- Home
- PCVX
PCVX
Vaxcyte Inc.
as 11-15-2024 3:38pm EST
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 13.2B | IPO Year: | 2020 |
| Target Price: | $147.50 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $48.24 - $121.06 | Next Earning Date: | 11-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vaxcyte Inc. (PCVX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PICKERING GRANT | PCVX | CHIEF EXECUTIVE OFFICER | Nov 7 '24 | Sell | $104.07 | 2,366 | $245,796.25 | 138,354 | |
| Wassil Jim | PCVX | CHIEF OPERATING OFFICER | Nov 1 '24 | Sell | $107.68 | 8,000 | $854,422.60 | 205,935 | |
| GUGGENHIME ANDREW | PCVX | PRESIDENT AND CFO | Oct 18 '24 | Sell | $115.73 | 42,000 | $4,846,508.21 | 96,269 | |
| PICKERING GRANT | PCVX | CHIEF EXECUTIVE OFFICER | Oct 7 '24 | Sell | $108.97 | 7,098 | $775,154.41 | 138,354 | |
| Eydelman Mikhail | PCVX | SVP, GEN COUNSEL & CORP SEC | Oct 7 '24 | Sell | $109.59 | 5,000 | $546,352.55 | 33,147 | |
| Wassil Jim | PCVX | CHIEF OPERATING OFFICER | Oct 1 '24 | Sell | $114.23 | 8,000 | $913,917.45 | 205,935 | |
| PICKERING GRANT | PCVX | CHIEF EXECUTIVE OFFICER | Oct 1 '24 | Sell | $114.20 | 55,000 | $6,283,860.79 | 138,354 | |
| Eydelman Mikhail | PCVX | SVP, GEN COUNSEL & CORP SEC | Oct 1 '24 | Sell | $114.25 | 5,500 | $628,294.76 | 33,147 | |
| GUGGENHIME ANDREW | PCVX | PRESIDENT AND CFO | Sep 18 '24 | Sell | $116.47 | 8,000 | $927,550.51 | 96,269 | |
| Loxam Teri | PCVX | Director | Sep 17 '24 | Sell | $116.02 | 6,250 | $726,730.95 | 11,739 |
Latest Vaxcyte Inc. News
PCVX Breaking Stock News: Dive into PCVX Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
Simply Wall St.
10 days ago
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
GuruFocus.com
11 days ago
Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight
GlobeNewswire
12 days ago
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
Insider Monkey
16 days ago
Should You Consider Investing in Vaxcyte (PCVX)?
MT Newswires
a month ago
Vaxcyte Insider Sold Shares Worth $4,846,508, According to a Recent SEC Filing
MT Newswires
a month ago
Vaxcyte Insider Sold Shares Worth $6,283,861, According to a Recent SEC Filing
MT Newswires
2 months ago
Vaxcyte Insider Sold Shares Worth $927,551, According to SEC Filing
Compare PCVX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PCVX Vaxcyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.